Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCENDI trial

Canadian Journal of Gastroenterology

Volumn 21, Issue 12, 2007, Pages 827-834

  Hanauer, Stephen B ^a   Sandborn, William J ^b   Dallaire, Christian ^c   Archambault, André ^d   Yacyshyn, Bruce ^e   Yeh, Chyon ^e   Smith Hall, Nancy ^e  

^a UNIVERSITY OF CHICAGO   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITÉ LAVAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Delayed release; Inflammatory bowel disease; Mesalamine; Ulcerative colitis

Indexed keywords

IMMUNOMODULATING AGENT; MESALAZINE; SALAZOSULFAPYRIDINE; STEROID;

ADULT; AGED; ARTICLE; CHOLECYSTITIS; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION HABIT; DELAYED DRUG RELEASE; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVARY CYST; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SMOKING; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; UTERUS MYOMA;

EID: 39149118880     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/862917     Document Type: Article

References (12)

1. Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of inflammatory bowel disease in Canada: A population-based study. Am J Gastroenterol 2006;101:1559-68. (Erratum in 2006;101:1945).
2. Langholz E, Munkholm P, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 1991;26:1247-56.
3. Kornbluth A, Sacher DB, for the Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99:1371-85.
4. Carter MJ, Lobo AJ, Travis SPL, for the IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl 5):V1-16.
5. Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: Comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990;31:1271-6.
6. Sandborn WJ, Hanauer SB. Systematic review: The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003;17:29-42.
7. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
8. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active colitis. A multicenter study. Ann Intern Med 1991;115:350-5.
9. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: Results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993;88:1188-97.
10. Asacol Product Monograph. Procter & Gamble Pharmaceuticals, Toronto, September 28, 2005.
11. Shikiar R, Rentz AM. Satisfaction with medication: An overview of conceptual, methodologic, and regulatory issues. Value Health 2004;7:204-15.
12. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial. Am J Gastroenterol 2005;100:2478-85.